Previous studies have demonstrated that these Ptpn11 gain-of-function (GOF) mutations are sufficient to drive the development of JMML-like myeloproliferative disorder (MPD) and malignant acute leukemias in mice [23], [26], [27], [28], [29]. Here, PTPN11 is linked to myeloproliferative disorder.